NCT04549649View on ClinicalTrials.gov

The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2022

Conditions
Ovarian StimulationReproductive Techniques, Assisted
Interventions
OTHER

Dual triggering

Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.

Trial Locations (1)

16635148

Royan Institute, Tehran

All Listed Sponsors
lead

Royan Institute

OTHER_GOV

NCT04549649 - The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response | Biotech Hunter | Biotech Hunter